In a small pilot study, intense immune reset led to prolonged insulin independence in the majority of recent-onset T1D patients (168). C-peptide production increased in all but one patient, with some patients remaining insulin-free for years. However, treatment carries significant risks (e.g. infection, chemotherapy side effects), limiting its broad applicability. The gene discussed is INS; the disease is type 1 diabetes mellitus.